Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

crizotinib

Known as: (R)-Crizotinib, 2-Pyridinamine, 3-((1R)-1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(4-Piperidinyl)-1H-Pyrazol-4-yl)-, (R)-3-(1-(2,6-Dichloro-3-Fluorophenyl)Ethoxy)-5-(1-(Piperidin-4-Yl)-1h-Pyrazol-4-Yl)Pyridin-2-Amine 
An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth… Expand
National Institutes of Health

Related topics

Related topics

11 relations
ALK protein, humanNCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase InhibitionReceptor Tyrosine Kinase Inhibitors [MoA]
Expand

Narrower (2)

PF-2341066Xalkori

Broader (3)

Protein Kinase InhibitorsPyrazolesPyridines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
ALK‐rearrangement in non‐small‐cell lung cancer (NSCLC)
The ALK gene encodes a transmembrane tyrosine kinase receptor. ALK is physiologically expressed in the nervous system during… Expand
Review
2018
Review
2018
Brigatinib versus Crizotinib in ALK‐Positive Non–Small‐Cell Lung Cancer
Background Brigatinib, a next‐generation anaplastic lymphoma kinase (ALK) inhibitor, has robust efficacy in patients with ALK… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
Highly Cited
2014
Highly Cited
2014
Crizotinib in ROS1-rearranged non-small-cell lung cancer.
BACKGROUND Chromosomal rearrangements of the gene encoding ROS1 proto-oncogene receptor tyrosine kinase (ROS1) define a distinct… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Highly Cited
2014
Highly Cited
2014
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.
UNLABELLED Non-small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements invariably develop… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2013
Highly Cited
2013
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
BACKGROUND In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK) have been associated… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Highly Cited
2012
Highly Cited
2012
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Multiple mechanisms of crizotinib resistance were identified in lung cancer patients including new secondary ALK mutations and… Expand
Highly Cited
2012
Highly Cited
2012
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer
Purpose: Patients with anaplastic lymphoma kinase (ALK) gene rearrangements often manifest dramatic responses to crizotinib, a… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Highly Cited
2012
Highly Cited
2012
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
BACKGROUND ALK fusion genes occur in a subset of non-small-cell lung cancers (NSCLCs). We assessed the tolerability and activity… Expand
Highly Cited
2011
Highly Cited
2011
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
BACKGROUND ALK gene rearrangement defines a new molecular subtype of non-small-cell lung cancer (NSCLC). In a recent phase 1… Expand
Highly Cited
2010
Highly Cited
2010
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
Inflammatory myofibroblastic tumor (IMT) is a distinctive mesenchymal neoplasm characterized by a spindle-cell proliferation with… Expand
  • figure 2
  • figure 3
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE